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Abstract
Epilepsy is a serious and common neurological disorder. Expression quantitative loci (eQTL) analysis is a vital aid for the
identification and interpretation of disease-risk loci. Many eQTLs operate in a tissue- and condition-specific manner. We
have performed the first genome-wide cis-eQTL analysis of human hippocampal tissue to include not only normal (n¼22)
but also epileptic (n¼22) samples. We demonstrate that disease-associated variants from an epilepsy GWAS meta-analysis
and a febrile seizures (FS) GWAS are significantly more enriched with epilepsy-eQTLs than with normal hippocampal eQTLs
from two larger independent published studies. In contrast, GWAS meta-analyses of two other brain diseases associated with
hippocampal pathology (Alzheimer’s disease and schizophrenia) are more enriched with normal hippocampal eQTLs than
with epilepsy-eQTLs. These observations suggest that an eQTL analysis that includes disease-affected brain tissue is advan-
tageous for detecting additional risk SNPs for the afflicting and closely related disorders, but not for distinct diseases affecting
the same brain regions. We also show that epilepsy eQTLs are enriched within epilepsy-causing genes: an epilepsy cis-gene
is significantly more likely to be a causal gene for a Mendelian epilepsy syndrome than to be a causal gene for another
Mendelian disorder. Epilepsy cis-genes, compared to normal hippocampal cis-genes, are more enriched within epilepsy-
causing genes. Hence, we utilize the epilepsy eQTL data for the functional interpretation of epilepsy disease-risk variants
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and, thereby, highlight novel potential causal genes for sporadic epilepsy. In conclusion, an epilepsy-eQTL analysis is supe-
rior to normal hippocampal tissue eQTL analyses for identifying the variants and genes underlying epilepsy.
Background
Epilepsy is amongst the most common neurological disorders,
affecting up to 1% of the population (1). Epilepsy is a complex
genetic disease: hundreds, perhaps thousands, of genetic vari-
ants influence susceptibility to epilepsy (2). A number of ge-
nome-wide association studies (GWAS) and a GWAS meta-
analysis have been conducted in order to identify genetic vari-
ants associated with common epilepsies, but have identi-
fied less than ten distinct loci (3). This lack of success is most
readily explained by the limited statistical power of GWAS (4):
many of the missing variants are likely to be hidden amongst
the signals discarded for failing to meet the stringent threshold
of statistical significance required to tackle the multiple testing
burden.
Expression quantitative trait loci (eQTL) analysis is a tool for
uncovering these hidden variants. eQTL studies are similar to
traditional genetic-association studies, but instead of associat-
ing genetic variants with discrete traits such as disease status,
eQTL studies correlate genetic variants with quantitative gene-
expression levels. It is known that disease-associated variants
are more likely to be eQTLs (5). By using this information, the
discovery of disease-associated variants can be enhanced as as-
sociation of a variant with gene expression lends credibility to
its association with disease status. eQTL-based selection for val-
idation has been shown to be a useful approach for identifying
disease-risk loci from GWAS in a number of disorders, for exam-
ple Crohn’s disease (6).
Another challenge in GWAS analysis is interpreting the bio-
logical relevance of susceptibility loci identified at genome-wide
levels of significance:>90% of disease-associated variants from
many GWAS lie in noncoding regions (7), making evaluation of
their function difficult. However, the expression of a high per-
centage of genes is regulated by DNA variants (8–10), and>75%
of significant GWAS variants map to regulatory regions in DNA
(7,11). Hence, identifying a relationship between disease-
associated genetic polymorphisms and gene expression levels
offers potential insights into the functional impact of these
variants.
Given that some eQTLs appear to be tissue-specific and
many disease phenotypes manifest themselves only in certain
tissues, the above approaches have been most successful when
eQTL analyses have been performed in disease-relevant tissues.
For example, eQTLs identified in immune (lymphoblastoid) cells
showed greater enrichment in disease-risk variants for autoim-
mune diseases than in disease-risk variants for neurological
disorders (5). In addition, the detection of some disease-
relevant eQTLs requires the assessment of disease-affected tis-
sue from subjects with the disease (12). Hence, eQTLs identified
in coronary artery disease-affected tissues match more coro-
nary artery disease-risk variants than eQTLs identified in the
same tissue-types isolated from healthy individuals (13). Only
two published eQTL studies have included samples from donors
with brain diseases (alongside normal samples): one included
tissue from donors with Alzheimer disease (14), while the other
included tissue from donors with various psychiatric diseases
(15). Neither of these studies assessed whether the inclusion of
disease samples enhanced the identification of disease-risk
variants.
We have performed the first genome-wide cis-eQTL
analysis to include epileptic brain samples. Importantly,
we have determined whether the inclusion of epileptic tis-
sue enhances the identification of epilepsy disease-risk
variants.
Results
Quality control and eQTL analysis overview
Three individuals were excluded from the eQTL analysis on
the basis of genotyping QC filters, and one further individual
was excluded from the eQTL analysis having failed the micro-
array QC criteria. We found no evidence of confounding effects
from population stratification: the eigenvalues of none of the
principal components reached statistical significance.
Additionally, none of the probe expression profiles were sig-
nificantly correlated with any of the top ten principal compo-
nents, demonstrating that the gene expression profile was not
significantly influenced by population stratification in this co-
hort (16). The final data-set, after quality control filtering, in-
cluded 22 epilepsy cases and 22 normal controls, and 4 663 226
genotyped and imputed single nucleotide polymorphisms
(SNPs). Patient characteristics are given in Supplementary
Material, Table S1.
0.5% (15698/2900609) of all genotyped and imputed cis-SNPs
were significant (FDR< 0.05) cis-eQTLs, and 3.95% of all ana-
lysed probes (748/18916) were significant (FDR< 0.05) cis-genes.
MIAME-compliant array data has been deposited in a publically
available database (ArrayExpress accession E-MTAB-3123). Full
eQTL results are provided as a Supplementary Material.
External validation of eQTL results
We determined if there was statistically significant replication
between the results of our eQTL analysis (epilepsy-eQTL) and
two independent published normal hippocampal tissue eQTL
analyses: the Genotype-Tissue Expression Project Version 6 (17)
analysis (GTEx) and the Braineac analysis (18). Replication with
GTEx was 122 times greater for the significant than the non-
significant SNP-gene pairs from the epilepsy-eQTL (Table 1).
Replication with Braineac was 40 times greater for the signifi-
cant than the non-significant SNP-gene pairs from the epilepsy-
eQTL (Table 1). The degree of replication with both GTEx and
Braineac was statistically significant (permutation-derived
P-value<1 x 104). Overall, 19.3% (279 out of 1448) of the inde-
pendent epilepsy-eQTL SNP-gene pairs were replicated in one of
the validation datasets.
Enrichment of eQTL results within GWAS SNPs
Epilepsy GWAS meta-analysis SNPs (18) that are more strongly
associated with the disease are more enriched with epilepsy-
eQTLs (Fig. 1A and Supplementary Material, Table S2). At the
point of maximal enrichment, epilepsy GWAS meta-analysis
SNPs were 147 times more enriched with epilepsy-eQTLs
than at baseline (GWAS P-value 1); this enrichment was statis-
tically significant (permutation-based P-value<1x104).
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In comparison, epilepsy GWAS meta-analysis SNPs were 3
times more enriched with normal hippocampus eQTLs at the
point of maximal enrichment than at baseline (GWAS P-value
1). The higher enrichment within epilepsy GWAS SNPs of
epilepsy-eQTLs, relative to normal hippocampus eQTLs, was
statistically significant (Supplementary Material, Table S3).
Febrile seizures (FS) GWAS (18) SNPs that are more strongly
associated with the disease are more enriched with epilepsy-
eQTLs (Supplementary Material, Fig. S1 and Supplementary
Material, Table S4). At the point of maximal enrichment, FS
GWAS SNPs were 125 times more enriched with epilepsy-
eQTLs than at baseline (GWAS P-value<1); this enrichment was
statistically significant (permutation-based P-value<1x104). In
comparison, FS GWAS SNPs were 2 times more enriched with
normal hippocampus eQTLs at the point of maximal enrich-
ment than at baseline (GWAS P-value<1). The higher enrich-
ment within FS GWAS SNPs of epilepsy-eQTLs, relative to
normal hippocampus eQTLs, was statistically significant
(Supplementary Material, Table S5).
On the other hand, the Alzheimer’s disease (AD)-(19) and
schizophrenia-associated (20) GWAS meta-analyses SNPs that
are more strongly associated with disease are more enriched
with GTEx normal hippocampus eQTLs than with epilepsy-
eQTLs (Fig. 1B–C and Supplementary Material, Table S2). Also,
epilepsy-eQTLs were more enriched within GWAS meta-
analyses SNPs associated with epilepsy than those associated
with AD or schizophrenia (Fig. 1D and Supplementary Material,
Table S2).
Table 1. Replication of epilepsy-eQTL gene-pairs
Validation
eQTL
study
Epilepsy-eQTL
FDR
Total number of
epilepsy-eQTL-gene
pairs (A)
Overlap with
validation
eQTL-gene pairs (B)
% of A
that overlaps
with B
Relative ratio of significant over non-significant
discovery eQTL-gene pairs that replicate
with validation gene-pairs
GTEx <0.05 764 121 15.84 122
0.05 295 944 385 0.13
Braineac <0.05 719 3 0.40 40
Figure 1. (A–C) Enrichment of significant SNPs from three eQTL studies (epilepsy-eQTL, GTEx and Braineac) within SNPs from three GWAS meta-analyses: epilepsy
(A), Alzheimer’s disease (B) and schizophrenia (C). (D) Enrichment of significant SNPs from the epilepsy-eQTL within SNPs from the three GWAS meta-analyses. Epi-
eQTL¼epilepsy-eQTL; AD¼Alzheimer’s disease; p-value notations as in the following example: 1e26¼1 x 1026.
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Enrichment of GWAS SNPs within eQTL results
Significant epilepsy-eQTL SNPs showed increasing enrichment
with epilepsy GWAS meta-analysis SNPs of progressively de-
creasing P-values (Fig. 2 and Supplementary Material, Table S6).
In addition, more significantly associated epilepsy-eQTL SNPs
were more enriched with epilepsy GWAS meta-analysis SNPs
(Fig. 2 and Supplementary Material, Table S6). Similarly, signifi-
cant epilepsy-eQTL SNPs showed increasing enrichment with
FS GWAS SNPs of progressively decreasing P-values
(Supplementary Material, Table S7), and more significantly as-
sociated epilepsy-eQTL SNPs were more enriched with FS
GWAS SNPs (Supplementary Material, Table S7).
Epilepsy eQTLs are enriched within Mendelian
epilepsy genes
An epilepsy cis-gene is 2.6x more likely to be a Mendelian gene
for epilepsy than a Mendelian gene for another disorder
(Supplementary Material, Table S8). This enrichment of epilepsy
eQTLs within causal genes for epilepsy is statistically significant
(two-sided Fisher’s exact test P-value< 0.05). In comparison, a
Braineac cis-gene is 1.4x more likely to be a causal gene for epi-
lepsy than to be a causal gene for another disorder, and a GTEx
cis-gene is 0.5x less likely to be a causal gene for epilepsy than
to be a causal gene for another disorder. The greater enrichment
within Mendelian epilepsy genes of epilepsy cis-genes, com-
pared to Braineac and GTEx cis-genes, is also statistically signif-
icant (permutation-based P-value< 0.05).
Using epilepsy-eQTL results to aid interpretation of
GWAS hits
One application of eQTL studies is to elucidate the genetic
causes of disease through corroboration of GWAS disease-risk
variants that achieve genome-wide level of significance, identi-
fication of disease-risk variants from amongst those failing to
reach genome-wide level of significance, and functional inter-
pretation of SNPs. Supplementary Material, Table S9 lists SNPs
that achieved at least nominal level of significance (P< 0.05) in
GWAS and were significant (FDR< 0.05) cis-eQTLs or were in
strong LD (r2 > 0.8) with significant eQTLs. From this list, we
highlight the most important examples below.
rs35476054 achieved a genome-wide level of significance (P-
value<3.99 x 109) in the epilepsy GWAS meta-analysis.
rs35476054 is an independent signal not in LD with other
genome-wide significant SNPs from the epilepsy GWAS meta-
analysis. rs35476054 is not a known eQTL. rs35476054 is in tight
LD (r2 ¼ 0.92) with rs12992163, which is a located in and is an
eQTL for TTC21B in our study, and leads to changes in multiple TF
binding motifs according to ENCODE (21). This SNP also shows a
suggestive association (P-value¼ 5 x 107) with febrile seizures in
an independent GWAS (22). Another SNP from the latter GWAS,
rs35049552, located just upstream of TTC21B, is significantly asso-
ciated with febrile seizures (P< 1.5 x 109), and is in tight LD (r2 ¼
0.96) with rs9332423, which is also eQTL for TTC21B in the current
study. rs9332423 leads to changes in TF binding motifs according
to ENCODE, and is an eQTL for TTC21B in AD brain tissue (23).
These disease SNPs are not in or in LD with SNPs from previous
hippocampal eQTL studies (15,17,18). TTC21B knockdown mice
exhibit major abnormalities in hippocampal structure (24). Also,
TTC21B mutations cause ciliopathies (25), and ciliary dysfunction
leads to neuronal excitability (26), spontaneous myoclonus (27)
and susceptibility to pentylenetetrazol-induced seizures in mice
(26,27). Ciliary dysfunction is seen in rodent models of epilepsy
(28) and human ciliopathies are associated with seizures (29–32).
Hence, our eQTL analysis reveals the potential functional impact
of these significantly disease-associated SNPs, and shows that
TTC21B is an important putative causal gene in both epilepsy and
febrile seizures.
rs11086166 is nominally associated (P< 0.05) with disease in
both the ILAE all epilepsy and focal epilepsy GWAS meta-
analyses. This SNP lies between two very proximate genes, be-
ing 837 bp 5’ of KCNQ2 and 14 kb 3’ of EEF1A2, and is a significant
(FDR< 0.05) cis-eQTL for both the genes in our analysis. There is
independent external evidence that these genes are under
shared regulatory control. Firstly, extensive microarray data col-
lated within Genevestigator (33) shows that KCNQ2 and EEF1A2
expression levels are positively correlated across all human tis-
sues (Pearson correlation coefficient r¼ 0.66), but more strongly
correlated in the brain (r¼ 0.81) and even more so in the tempo-
ral lobe (r¼ 0.92). Hippocampal tissue constituted 61% (165/271)
of the samples included in the temporal lobe analysis; an analy-
sis restricted to hippocampal tissue was not enabled within
Genevestigator. Secondly, there is evidence that both genes are
co-regulated in the brain by another cis-eQTL, rs141448165, ac-
cording to the Braineac eQTL analysis: rs141448165 is an eQTL
for KCNQ2 (nominal P-value¼ 1.9 x 105) and EEF1A2 (nominal
P-value¼ 3.0 x 105) in intralobular white matter. rs11086166 is
in strong LD (r2¼ 0.91) with rs884851 which is a cis-eQTL for
KCNQ2 in lymphoblastoid cells (34). Numerous distinct muta-
tions and deletions affecting KCNQ2 (35–51) or EEF1A2 (52–57) or
both (58,59) are known to cause Mendelian familial epilepsy
syndromes or childhood epileptic encephalopathies. KCNQ2 is a
voltage-gated non-inactivating potassium ion channel that is
downregulated in the epileptic human hippocampus (60,61).
Drugs activating these channels reduce neuronal excitability
and have antiepileptic efficacy (62). Retigabine, a positive allo-
steric modulator of KCNQ2, has recently been licenced for the
treatment of epilepsy (63). EEF1A2 is a tissue-specific translation
elongation factor expressed only in neurons, cardiac and skele-
tal muscle (64). EEF1A2-mutant mice exhibit abnormal neuro-
transmitter uptake and release, demyelination and gliosis (64).
rs11941935 is nominally associated (P< 0.05) with disease in
the ILAE focal epilepsy GWAS meta-analysis. rs11941935 lies
3.9 kb 3’ of LIAS and is a significant (FDR< 0.05) cis-eQTL for this
gene in our analysis. According to independent published studies,
rs11941935 is a significant cis-eQTL for LIAS in blood (34,65,66),
skin (34) and adipocytes (34). Different mutations in LIAS cause
Figure 2. Relative enrichment of epilepsy GWAS meta-analysis SNPs within epi-
lepsy-eQTL SNPs.
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severe syndromes characterized by the development of seizures,
epilepsy and epileptic encephalopathy (67,68). LIAS-mutant mice
display prominent abnormalities in brain morphology (69).
The above observations suggests that genetic variation in
KCNQ2, EEF1A2 and LIAS, known to cause familial epilepsy syn-
dromes or epileptic encephalopathies, might also play a role in
the development of sporadic focal epilepsy.
Analysis of the epilepsy GWAS and eQTL results using
Sherlock (70), a tool which detects disease genes by integrating
GWAS and eQTL data, corroborated the association between
TTC21B and epilepsy (Log Bayes Factor¼ 5.45, P-value¼ 1.7 x
105, FDR¼ 0.01). Other genes showed more modest associa-
tions in the Sherlock analysis (P-values 0.001). These findings
are in keeping with previously reported results from the crea-
tors of Sherlock: only one gene met their predefined criteria of
P< 1 x 104 (FDR< 0.09) for association with Crohn’s disease,
when considering cis-SNPs only (70). Complete results from our
Sherlock analysis are detailed in Supplementary Material,
Table S10.
Discussion
The contributions of this study are 3-fold. Firstly, this study ob-
jectively demonstrates that epilepsy disease-risk SNPs are sig-
nificantly more enriched in an eQTL analysis of disease-affected
brain tissue from people with epilepsy than in eQTL analyses of
the same tissue types from unaffected donors. Secondly, we use
the results of our disease-specific eQTL analysis to provide
novel insights into the genetic causes of epilepsy. Thirdly, the
full epilepsy-eQTL results are released as a novel resource to aid
the interpretation of other findings from current and future
GWAS analyses of epilepsy.
It is known that eQTLs identified in disease-relevant tissue
types from normal donors are more enriched in disease-risk loci
than eQTLs identified in non-relevant tissue types (5). In addi-
tion, it has been suggested that including in the eQTL analysis
disease-tissue from donors with the disease enhances the de-
tection of disease-risk variants. A recent study found that
eQTLs identified in coronary artery disease-affected tissues
match more coronary artery disease-risk variants than eQTLs
identified in the same tissue-types isolated from healthy indi-
viduals, although they did not determine if the difference is sta-
tistically significant (13). We are not aware of a similar
published analysis with brain tissue eQTLs. As with our analy-
sis, Webster et al. (14) included disease-relevant tissue from do-
nors with and without the disease. They showed that inclusion
of tissue from individuals with the disease led to the detection
of some eQTLs not otherwise identified. The authors did not de-
termine, however, if this strategy leads to the identification of
more disease-associated variants. Intuitively, the inclusion of
both normal and pathological tissue should enhance the ability
to detect disease-related eQTLs as the datasets analysed will
capture the transcriptomic and genotypic differences between
patients and controls. Hence, we performed a genome-wide cis-
eQTL analysis that included epileptic human hippocampal tis-
sue. We found that this epilepsy-eQTL analysis is superior to
normal hippocampal tissue eQTL analyses for the detection of
epilepsy disease-risk loci: epilepsy-eQTLs were significantly
more enriched with epilepsy disease-risk variants than eQTLs
from larger normal hippocampal analyses (Fig. 1A). These find-
ings are unlikely to be spurious as epilepsy-eQTLs were signifi-
cantly more enriched than normal hippocampal tissue eQTLs in
a completely independent GWAS of FS. To further demonstrate
that eQTLs identified in disease-effected tissue are of most
relevance to the afflicting disease, we also showed that disease-
risk loci for two brain diseases with proven hippocampal in-
volvement, AD (71) and schizophrenia (72), were less enriched
with hippocampal epilepsy-eQTLs than with normal hippocam-
pal eQTLs (Fig. 1B–D). These observations suggest that an eQTL
analysis of disease-affected brain tissue is advantageous for de-
tecting additional risk SNPs for the afflicting and closely related
diseases, but not for distinct disorders affecting the same brain
regions. This highlights the need to perform disease-specific
eQTL analyses in other brain diseases.
We studied the relationship of epilepsy eQTLs to known hu-
man disease genes that cause familial Mendelian disorders. We
found that epilepsy eQTLs are enriched within Mendelian epi-
lepsy genes: an epilepsy cis-gene is significantly more likely to
be a causal gene for a Mendelian epilepsy syndrome than to be
a causal gene for another Mendelian disorder. The enrichment
within causal epilepsy genes of epilepsy cis-genes, compared to
that of Braineac and GTEx cis-genes, is greater than expected by
chance alone. It has been shown recently that genes known to
cause Mendelian familial forms of a disease can contribute to
sporadic forms of the disease (73). Hence, these observations
lend support to the disease-specific pathogenic nature of epi-
lepsy eQTLs. There is an increasing interest in identification of
functionally relevant genes through integration of GWAS and
eQTL summary results, and specialized analytical approaches
are being developed for this purpose (74). Such approaches may
benefit from the use of disease-specific eQTL results; this should
be investigated in future studies.
One of the applications of eQTL studies is to reveal disease-
causing genes by identifying cis-SNPs that corroborate GWAS
disease-risk variants and then link them to cis-genes of poten-
tial causal relevance. In epilepsy, as with other complex genetic
diseases, for example, schizophrenia, thousands of genetic vari-
ants potentially influence disease susceptibility (2). A compre-
hensive recent epilepsy GWAS meta-analysis, which included
8696 cases, reported two independent loci at genome-wide level
of significance (4). Many of the missing variants are likely to be
hidden amongst the signals discarded for failing to meet the
stringent threshold of statistical significance required to tackle
the multiple testing burden. eQTL studies, such as this one, that
include epileptic tissue are vital to the identification of novel ep-
ilepsy disease-risk variants from amongst SNPs failing to reach
genome-wide level of significance. Supplementary Material,
Table S9 lists SNPs that achieved at least nominal level of signif-
icance (P< 0.05) in GWAS and were significant (FDR< 0.05)
epilepsy-eQTLs, along with their respective cis-genes. As larger
multinational epilepsy GWAS collaborations that are currently
in progress (www.epipgx.eu) start to generate results, this list of
potentially causal SNPs will increase, as will the utility of our
epilepsy-eQTL analysis.
Examining individual GWAS variant-eQTL associations, an im-
portant finding of our study is that a top epilepsy SNP and a top FS
SNP, both associated with their respective phenotype at genome-
wide level of significance, are cis-eQTLs for TTC21B. Hence, TTC21B
is potentially an important causal gene underlying both epilepsy
and FS. This assertion is supported by the following observations.
These cis-SNPs lead to changes in multiple TF binding motifs (21),
there is corroboration of at least one of the cis-eQTLs from an inde-
pendent analysis (22), and TTC21B mutations cause major hippo-
campal morphological abnormalities in rodents (24) and ciliary
dysfunction (25), which promotes seizures in animal models and
man (26,27–32). Given the paucity of statistically significant gene
associations with sporadic epilepsy, TTC21B is an especially valu-
able addition.
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Another notable finding is that some nominally disease-
associated SNPs are significant eQTLs for genes implicated in
monogenic Mendelian epilepsy syndromes: KCNQ2, EEF1A2 and
LIAS. A number of observations make these compelling poten-
tial causal genes in sporadic epilepsy. The eQTL associations
are corroborated by data from independent published studies
(34,65,66). The effect of their dysfunction in animal models is
congruent with enhanced seizure susceptibility (64,69). Many
different mutations and deletions affecting these genes produce
a number of syndromes characterized by the development of
seizures, epilepsy and epileptic encephalopathy (35–59,67,68). It
has been shown recently that genes known to cause Mendelian
familial forms of a disease can contribute to sporadic forms of
the disease (73). Indeed, one of the associations reported by the
all epilepsy GWAS meta-analysis was with SCN1A (4), which is
implicated in some monogenic epilepsies and is targeted by a
number of conventional antiepileptic drugs (75). These points
indicate that KCNQ2, EEF1A2 and LIAS are particularly promising
leads in the search for causal genes and therapeutic targets in
sporadic epilepsy. Indeed, KCNQ2 is targeted by a drug recently
licenced for the treatment of epilepsy, retigabine, which is effi-
cacious is sporadic epilepsy (63).
It might be deemed intuitive and expected that an eQTL
analysis that includes disease-affected brain tissue will be more
disease-relevant. However, demonstrating this objectively is of
value as it evidences and stresses the need to include disease-
affected brain tissue in future eQTL studies and the advantages
of such a strategy. We acknowledge that we have analysed a rel-
atively small number of samples. We would advocate future
epilepsy-eQTL analyses with larger numbers of samples in order
to confirm our findings and to discover new eQTLs. We are
aware of a recent study that included a limited trans-eQTL anal-
ysis of epileptic brain tissue in order to identify SNPs regulating
specific gene co-expression modules that they had deemed to
be important (76); that study does not include genome-wide cis-
eQTL SNPs and targets.
Conclusions
In conclusion, we have presented the first genome-wide cis-eQTL
analysis to include epileptic human hippocampal tissue. We have
shown that this epilepsy-eQTL analysis is superior to normal hip-
pocampal tissue eQTL analyses for the detection and interpreta-
tion of epilepsy disease-risk variants and genes, and provides
novel insights into the genetic causes of epilepsy. Our results high-
light the need to perform disease-specific eQTL studies in other
brain diseases and to perform larger epilepsy-eQTL studies.
Materials and Methods
Collection of human hippocampal samples, RNA
isolation, microarray processing, and microarray data
normalization, adjustment and filtering
A brief summary of these steps is presented here; a detailed de-
scription can be found in our previous publication (60). The
study was approved by the Northwest 2 Research Ethics
Committee. Informed consent was obtained from tissue donors.
Epileptic hippocampal samples were obtained from patients un-
dergoing therapeutic resection for refractory mesial temporal
lobe epilepsy. Frozen post-mortem histologically-normal hippo-
campal samples from donors with no known brain diseases
were obtained from tissue banks. RNA isolated from hippocam-
pal samples was analysed using Agilent SurePrint G3 Custom
8x60K Microarrays designed to contain probes for all known
genes. Batch effect was corrected using the ComBat (77) algo-
rithm. To adjust for known and unknown confounders,
Independent Surrogate Variable Analysis (78) was applied; RIN,
age and sex were explicitly included in the ISVA adjustment.
Where multiple probes mapped to the same gene, the probe
with the highest variance was retained, as the most variant
probe is likely to be most informative.
Polymorphisms present in the probe-target sequences have
been shown to alter probe hybridization affinities, leading to re-
duced signal intensity measurements and resulting in false-
positive results (79). We used the ‘PIP Finder’ tool (79) to deter-
mine which probes in our microarray had polymorphisms with
a minor allele frequency>1% in Europeans located within the
probe sequences; all such probes were excluded from the eQTL
analysis in keeping with current practice.
DNA isolation, genotyping, quality control
and imputation
DNA was extracted from brain samples using the DNeasy
Blood & Tissue Kit (Qiagen, Crawley, United Kingdom)
according to the manufacturer’s recommended protocol.
All samples were genotyped on the Illumina Infinium
HumanOmniExpressExome BeadChip in the ARK Genomics fa-
cility at the Roslin Institute, UK. Per-SNP and per-individual
quality control (QC) procedures were applied, as detailed in
the Supplementary Material.
Genotype imputation was performed using Impute2 (80),
with 1000 Genomes Project haplotypes (March 2012) as the ref-
erence panel. The QCTOOL software was used to exclude SNPs
with an ‘info’ score of<0.9. GTOOL software was then used to
transform the imputed data to PED format, with a posterior
probability of 0.9 used as a threshold to call genotypes. Our
standard per-SNP QC filters, as detailed in the Supplementary
Material, were then applied.
eQTL analysis
eQTL analysis was performed using the linear model in the pro-
gram Matrix eQTL (81). We defined cis-SNPs as those within 20 kb
of the target gene. There is no consensus (82), amongst re-
searchers, on the distance cut-off relative to the regulated gene
used to define cis-SNPs, with distances ranging from 20 kb (83–86)
to 1 Mb (87), or even longer (88,89), being found in published liter-
ature. We opted for the conservative end of this range as cis-
eQTLs rarely reside more than 20 kb away from the gene (90), and
cis-eQTL effect sizes (91,92) and replication rates (18) decay (and,
inversely, false positives increase) with increasing distance from
the target gene. Threshold of statistical significance was set at
Benjamini–Hochberg False Discovery Rate (FDR)< 0.05. To investi-
gate potential confounding effects from population stratification,
the principal components (PC) of variance of the genotyping data-
set were calculated using the package SNPRelate (93), and then
the Tracy-Widom (TW) statistic (94) and significance for the ei-
genvalue of each PC was calculated using the package EigenCorr
(95). Furthermore, the top ten PCs were separately correlated with
the probe expression profiles in R.
Datasets for validation and enrichment analyses
For validation, hippocampal eQTLs were extracted from the
published results of the Genotype-Tissue Expression Project
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Version 6 (GTEx) (17) and the Braineac study (18); these are the
largest eQTL analyses of normal human hippocampal tissue
published to date, including 81 and 134 samples, respectively.
For enrichment analyses, complete results from the largest
GWAS meta-analyses of epilepsy (4), Alzheimer’s disease (AD)
(19) and schizophrenia (20) were downloaded. Complete results
from a recent GWAS of febrile seizures (FS) (22) were also used
for enrichment analysis; these results have not been publicly re-
leased, hence, scripts were provided to the authors and run on
the FS GWAS results by them.
External validation of eQTL results
We determined if there is statistically significant replication be-
tween the results of our eQTL analysis (epilepsy-eQTL) and the
GTEx normal human hippocampus eQTL analysis. We deter-
mined the fraction of statistically significant (FDR<0.05) SNP-
gene pairs from the epilepsy-eQTL that were replicated in GTEx.
For comparison, we determined the fraction of non-significant
(FDR 0.05) SNP-gene pairs from the epilepsy-eQTL that were
replicated in GTEx. For these comparative analyses, we included
only the SNPs analysed in both eQTL studies, and LD-pruned
the SNPs. To enable comparison between the two studies, all
gene identifiers were converted to Entrez Gene IDs. To deter-
mine the statistical significance of the replication, a
permutation-based approach was adopted, which is detailed in
Supplementary Material. Briefly, 10 000 sets of randomly-
chosen epilepsy-eQTL SNP-gene pairs were created and their
overlap with significant SNP-gene pairs from GTEx was
determined.
Using the aforementioned methods, we also determined if
there is statistically significant replication between the results
of the epilepsy-eQTL and the Braineac eQTL analysis. It should
be noted that the authors of Braineac have provided only LD-
pruned eQTL results; these were used to determine the statisti-
cal significance of replication with the epilepsy-eQTL.
The total number of independent epilepsy-eQTLs that were
replicated in either the GTEx or Braineac analyses was also cal-
culated. We created an LD-pruned list of epilepsy-eQTL SNP-
gene pairs. Epilepsy-eQTL SNP-gene pairs also found in one of
the validation eQTLs were deemed replicated. Also considered
replicated were epilepsy-eQTL SNP-gene pairs where the SNP
was in high LD (r2 > 0.8) with a different SNP that was an eQTL
for the same gene in one of the validation datasets.
Enrichment of eQTL results within GWAS SNPs
Enrichment of eQTL results within GWAS SNPs was calculated
using previously published methodology (96,97), which is de-
tailed in the Supplementary Material. Briefly, a list of SNPs
included both in the ILAE GWAS meta-analysis and the
epilepsy-eQTL was created. This list was LD-pruned. For the
GWAS SNPs that remained after LD-pruning, the fraction that
were significant eQTLs was calculated for a range of GWAS P-
values. At the point of maximal enrichment, the statistical sig-
nificance of the overlap between disease SNPs and eQTLs was
calculated using a permutation-based approach. Another
permutation-based analysis was completed in order to deter-
mine if the higher enrichment of the epilepsy-eQTL SNPs, com-
pared to GTEx SNPs, within the epilepsy GWAS was statistically
significant (please see Supplementary Material).
The above processes were repeated for the epilepsy-eQTL
and Braineac analyses. The above analyses were also repeated
for the FS GWAS.
Enrichment of GWAS SNPs within eQTL results
We determined if significant epilepsy-eQTLs were enriched
with significant epilepsy GWAS meta-analysis SNPs. A list of
SNPs included both in the ILAE GWAS meta-analysis and the
epilepsy-eQTL analysis was created and LD-pruned. From this
list, we calculated the fraction (f1) of SNPs with GWAS P-val-
ue<1 x 106. We created a subset of SNPs with epilepsy-eQTL
FDR< 0.05, and calculated the fraction (f2) of SNPs with GWAS
P-value<1 x 106 in this subset. The relative enrichment of sig-
nificant epilepsy GWAS meta-analysis SNPs within significant
epilepsy-eQTLs was defined as f2/f1. These calculations were re-
peated for a range of epilepsy GWAS meta-analysis P-values
and epilepsy-eQTL FDRs. In the rare situation that a SNP ap-
peared more than once in the epilepsy-eQTL results, the lowest
FDR for the SNP was used.
Enrichment of eQTLs within human disease genes
We studied the relationship of epilepsy eQTLs to known human
disease genes that cause familial Mendelian disorders. Genes
known to cause Mendelian human diseases were extracted
from the Online Mendelian Inheritance in Man (OMIM) Morbid
Map (omim.org/downloads; date last accessed September 01,
2016) and mapped to Entrez gene identifiers. Within this list,
genes that cause Mendelian epilepsy syndromes—disorders in
which epilepsy or seizures are a cardinal feature—were identi-
fied. The enrichment of epilepsy eQTLs within causal genes for
epilepsy, compared to causal genes for other diseases, was de-
termined. Specifically, the proportion of Mendelian epilepsy
genes that are epilepsy cis-genes, and the proportion of other
Mendelian genes that are epilepsy cis-genes was calculated.
The two proportions were compared using a two-sided Fisher’s
exact test, with the level of statistical significance set at P-
value< 0.05.
Using the above procedure, the enrichment of Braineac
eQTLs within Mendelian epilepsy genes and the enrichment of
GTEx eQTLs within Mendelian epilepsy genes was calculated.
Within Mendelian epilepsy genes, epilepsy cis-genes were en-
riched more than Braineac and GTEx cis-genes; the statistical
significance of the relative enrichment was determined using
permutation-based analysis (please see Supplementary
Material).
Functional interpretation of GWAS results
In order to demonstrate the utility of the epilepsy-eQTL dataset
for the functional interpretation of specific findings from rele-
vant GWAS analyses, we identified examples of variant(s) fail-
ing to reach genome-wide level of significance in the epilepsy
GWAS meta-analysis but revealed to be putatively functionally
relevant using the epilepsy-eQTL results, and variant(s) reach-
ing genome-wide level of significance in the epilepsy GWAS
meta-analysis whose functional relevance and effect is revealed
only by utilizing epilepsy-eQTLs. ENCODE data was interrogate
using HaploReg (19) in order to determine if eQTLs produce
changes in transcription factor (TF) binding motifs.
Genevestigator (33) co-expression tool was used to determine
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the similarity between the transcriptomic profiles of KCNQ2 and
EEF1A2 (see Results).
Epilepsy GWAS meta-analysis and epilepsy eQTL results
were submitted to Sherlock (http://sherlock.ucsf.edu/; date last
accessed December 11, 2016) (70), an analytical tool for detecting
disease genes by integrating eQTL and GWAS data.
Supplementary Material
Supplementary Material is available at HMG online.
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